{"filings":[{"id":890396,"accession_number":"0002019410-26-000046","cik":2019410,"company_name":"Caris Life Sciences, Inc.","ticker":"CAI","form_type":"8-K","filed_at":"2026-06-05T21:03:34+00:00","items":["5.07"],"status":"ready","headline":"Caris Life Sciences shareholders elect ten directors, ratify Deloitte as auditor for FY2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual Meeting held June 4, 2026; 273.7M shares represented (96.8% of 282.7M outstanding).","All ten director nominees elected with votes ranging from 200.4M to 228.7M in favor.","Deloitte & Touche LLP ratified as independent auditor: 273.5M for, 60.9K against, 136.3K abstentions.","Broker non-votes of 11.1M recorded on director election but not on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":4627483004.717164,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97234,"accession_number":"0002019410-26-000040","cik":2019410,"company_name":"Caris Life Sciences, Inc.","ticker":"CAI","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Caris Life Sciences Q1 revenue up 79% to $216.2M, net loss narrows to $0.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $216.2M (+79% YoY); gross margin 65% vs 47% a year ago.","Net loss $0.5M vs $102.6M loss in Q1 2025; positive Adj. EBITDA $26.2M.","Completed ~52,800 clinical cases (+15% YoY); reaffirms FY2026 revenue guidance $1.0-$1.02B.","Free cash flow positive $22.5M, inclusive of $30.5M annual bonus payments.","Launched MolDX-approved Caris ChromoSeq; refinanced $400M credit facility with Blue Owl/Blackstone."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":216174000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4627483004.717164,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97233,"accession_number":"0002019410-26-000019","cik":2019410,"company_name":"Caris Life Sciences, Inc.","ticker":"CAI","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["1.01","1.02","2.03"],"status":"ready","headline":"Caris Life Sciences enters $400M term loan and $300M delayed draw facility with Blue Owl and Blackstone","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Borrowed $400M initial term loan to repay existing credit agreement from January 2023.","Additional $300M delayed draw facility for acquisitions available through August 2027.","Uncommitted incremental capacity up to $500M; loans priced at SOFR + 5.00%.","Credit agreement matures April 2031; secured by substantially all assets.","Must maintain minimum $50M qualified cash tested quarterly."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4627483004.717164,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111833,"accession_number":"0002019410-26-000011","cik":2019410,"company_name":"Caris Life Sciences, Inc.","ticker":"CAI","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Caris Q4 net income $82M; FY25 rev $812M (+97%); guides FY26 rev $1.0-1.02B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $292.9M (+125% YoY); net income $82.0M vs loss of $36.9M prior year.","Full year 2025 revenue $812.0M (+97% YoY); net loss narrowed to $68.1M from $281.9M; Adj. EBITDA $137.7M.","Gross margin improved to 75% in Q4 (from 54%) and 66% for FY (from 43%).","FY26 revenue guidance $1.0-1.02B (23-26% growth); molecular profiling rev growth ~21-22%.","Interim readout of Achieve 1 study for Caris Detect MCED test completed; launch expected H1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":812033000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":4627483004.717164,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111832,"accession_number":"0002019410-26-000005","cik":2019410,"company_name":"Caris Life Sciences, Inc.","ticker":"CAI","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Caris Life Sciences reports preliminary Q4 2025 revenue of ~$281M, up 116% YoY; FY revenue ~$800M, up 94%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue ~$281M (+116% YoY); Molecular Profiling services ~$270M including ~$81M prior-period true-ups.","Full-year 2025 revenue ~$800M (+94% YoY); Pharma R&D services ~$45M.","Q4 clinical therapy selection cases ~52,700 (+20%); full-year ~199,300 (+22%).","Cash, equivalents and marketable securities ~$802M as of Dec 31, 2025, up ~$43M from Sep 30, 2025.","Company presenting at 44th J.P. Morgan Healthcare Conference today; complete earnings call expected in late Feb 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":812033000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":4627483004.717164,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128457,"accession_number":"0002019410-25-000026","cik":2019410,"company_name":"Caris Life Sciences, Inc.","ticker":"CAI","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Caris Life Sciences Q3 revenue $216.8M, up 113%, raises FY2025 guidance to $720-730M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $24.3M vs. loss of $67.7M YoY; diluted EPS $0.08 vs. ($2.59).","Gross margin expanded to 68.0% from 43.7% YoY; clinical cases up 18.2% to 50,763.","Positive Adjusted EBITDA of $51.2M and free cash flow of $55.3M.","Full-year 2025 revenue guidance raised to $720-730M, representing 75-77% YoY growth.","Molecular profiling services revenue grew 121.3% YoY to $207.6M."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":519147000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":4627483004.717164,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128456,"accession_number":"0002019410-25-000020","cik":2019410,"company_name":"Caris Life Sciences, Inc.","ticker":"CAI","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Caris Life Sciences adopts 3% ownership threshold for derivative proceedings","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved amendment to bylaws on October 30, 2025 requiring 3% beneficial ownership to institute or maintain a derivative proceeding.","Threshold applies to any shareholder or group of shareholders acting together under the Texas Business Organizations Code.","Changes are effective immediately; full text of amended bylaws filed as Exhibit 3.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":4627483004.717164,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145253,"accession_number":"0002019410-25-000011","cik":2019410,"company_name":"Caris Life Sciences, Inc.","ticker":"CAI","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Caris Life Sciences Q2 2025 revenue $181.4M (+81% YoY); Adj. EBITDA positive $16.7M; FY rev guidance $675-685M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $181.4M, up 81.3% YoY; gross margin 62.7% vs 37.5% a year ago.","Net loss $71.8M includes $37.1M one-time IPO conversion expense; positive Adj. EBITDA $16.7M and positive free cash flow $5.9M.","Clinical therapy selection volume 50,032 cases (+22% YoY); MI Profile volume +17.7%, Caris Assure volume +56.3%.","FY2025 revenue guidance $675-685M (64-66% growth); clinical volume growth expected 19-21%.","Recent IPO raised $519.5M net; cash and securities $724.9M at June 30, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-12.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":302314000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4627483004.717164,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163674,"accession_number":"0001104659-25-061148","cik":2019410,"company_name":"Caris Life Sciences, Inc.","ticker":"CAI","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"Caris Life Sciences completes IPO of 23.5M shares at $21.00, raising $494.1M gross","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IPO of 23,529,412 shares of common stock at $21.00 per share closed June 20, 2025.","Gross proceeds of $494.1 million before underwriting discounts and estimated offering expenses.","Amended and restated certificate of formation and bylaws became effective upon IPO closing.","Shares trade on Nasdaq under ticker CAI."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":4627483004.717164,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}